Courtney Rehak
Affiliations: | Cognition Therapeutics |
Area:
Alzheimer's Disease Drug DiscoveryGoogle:
"Courtney Rehak"Mean distance: 106866 (cluster 11) | S | N | B | C | P |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Rishton GM, Look GC, Ni ZJ, et al. (2021) Discovery of Investigational Drug CT1812, an Antagonist of the Sigma-2 Receptor Complex for Alzheimer's Disease. Acs Medicinal Chemistry Letters. 12: 1389-1395 |
| LaBarbera KM, Limegrover C, Rehak C, et al. (2021) Modeling the mature CNS: A predictive screening platform for neurodegenerative disease drug discovery. Journal of Neuroscience Methods. 358: 109180 |
| Izzo NJ, Yuede CM, LaBarbera KM, et al. (2021) Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification. Alzheimer's & Dementia : the Journal of the Alzheimer's Association |
| Limegrover CS, Yurko R, Izzo NJ, et al. (2021) Sigma-2 receptor antagonists rescue neuronal dysfunction induced by Parkinson's patient brain-derived α-synuclein. Journal of Neuroscience Research |
| Limegrover CS, LeVine H, Izzo NJ, et al. (2020) Alzheimer's Protection Effect of A673T Mutation May Be Driven by Lower Aβ Oligomer Binding Affinity. Journal of Neurochemistry |
| Izzo NJ, Xu J, Zeng C, et al. (2014) Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers II: Sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity. Plos One. 9: e111899 |
| Izzo NJ, Staniszewski A, To L, et al. (2014) Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits. Plos One. 9: e111898 |